BUZZ-India's Glenmark Pharma falls after agreeing to $29.6 million settlement in US

** Shares of Glenmark Pharmaceuticals GLEN.NS fall as much as 2.5% to 2,229 rupees; set for the third session of losses

** A coalition of 48 states and territories in the United States reached a $29.6 million settlement with GLEN and will make installment payments through 2030

** They accuse the co of helping inflate prices of generic drugs and limiting competition

** GLEN denied wrongdoing but agreed to cooperate with ongoing state lawsuits and make changes to ensure compliance with antitrust law

** Ten analysts have a "Buy" rating on average; median PT is 2,575 rupees - data compiled by LSEG

** YTD, GLEN up 10.5%


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.